TABLE 1.
Angiogenesis-related miRNAs responsible for GBM.
| MiRNA | Loci | Expression status (up/down) | Targets | Models (in vitro, in vivo, human) | Kind of the cell-line | Reference |
| miR-125b | chr11: q24.1–q24.1 | Down | VEGF | In vitro | Co-culture of HBMVECs, ACBRI-376, U87 | Smits et al., 2012 |
| miR-129-5p | chr7: q32.1–q32.1 | Down | Wnt5a | Human, in vitro, in vivo | U251, LN229, A172, LN18, T98G | Zeng et al., 2018 |
| miR-421 | chrX: q13.2–q13.2 | Down | MEF2D | Human, in vitro, in vivo | U251, U87 | Liu et al., 2017 |
| miR-1301-3p | chr2: 25551509–25551590 | Down | N-Ras | Human, in vitro, in vivo | U87, U251, U118, LN229, A172, H4 | Zhi et al., 2017b |
| miR-518b | chr19: q13.42–q13.42 | Down | PDGFRB | Human, in vitro, in vivo | U87, U251 | Xu X. et al., 2017 |
| miR-107 | chr10: q23.31–q23.31 | Down | VEGF | In vitro, in vivo | U87, A172 | Chen L. et al., 2016 |
| miR-29c | chr1: q32.2–q32.2 | Down | VEGF | Human, in vitro | U251, U87, T98G, A172, SHG44 | Fan et al., 2013 |
| miR-7-5p | chr9: q21.32–q21.32 | Down | RAF1 | Human, in vitro | HUV-EC-C, 293T | Liu et al., 2014 |
| miR-566 | chr3: 50210759–50210852 | Up | VHL | In vitro, in vivo | U87 | Xiao et al., 2016 |
| miR-613 | chr12: p13.1–p13.1 | Down | VEGFA | Human, in vitro, in vivo | NHA, H4, U87, U251, SWO-38 | Yu and Wang, 2017 |
| miR-124-5p | chr8: p23.1–p23.1 | Down | LAMB1 | Human, in vitro, in vivo | U87, U251 | Chen Q. et al., 2014 |
| miR-124 | chr8: p23.1–p23.1 | Down | R-RAS, N-RAS | Human, in vitro, in vivo | U87, U251 | Shi et al., 2014 |
| miR-101 | chr1: p31.3–p31.3 | Down | EZH2 | In vitro, in vivo | HBMVEC, C6, 293T, MCF-7, U118, U251, U373, U87 | Smits et al., 2010 |
| miR-143 | chr5: q32–q32 | Down | N-RAS | Human, in vitro, in vivo | U87, U251, HEK-293T | Wang L. et al., 2014 |
| miR-558 | chr2: p22.3–p22.3 | Up | AGO2, eIF4E, HIF-2α | Human, in vitro, in vivo | NB-1643, SK-N-BE(2), NB-1691, IMR32, BE(2)-C, SK-N-AS, SH-SY5Y, SK-N-SH, HUVEC | Qu et al., 2016 |
| miR-145 | chr5: q32–q32 | Down | In vitro, in vivo | HMEC, U87 | Lu et al., 2015 | |
| miR-5096 | Locus is not confident. | Up | Cx43 | In vitro, in vivo | HMEC, U87 | Thuringer et al., 2016 |
| miR-137 | chr1: p21.3–p21.3 | Down | EZH2 | Human, in vitro, in vivo | H4, U251, HUVEC, U87 | Sun et al., 2015 |
| miR-378 | chr5: q32–q32 | Up | VEGFR2 | In vitro, in vivo | U87-miR-378, U87-GFP | Jamali et al., 2018 |
| miR-520d-5p | chr19: 53720096–53720182 (+) | Down | PTTG1 | Human, in vitro, in vivo | U87, U251, U118, LN229, A172, H4 | Zhi et al., 2017a |
| miR-296 | chr20: q13.32–q13.32 | Up | PDGFR; VEGFR; HGS | In vitro, in vivo | HBMVEC, HUVEC, U87, 293T | Würdinger et al., 2008 |
| miR-23b | chr9: q22.32–q22.32 | Up | VHL | In vitro, in vivo | U87, LN229, U251, HUVEC | Chen L. et al., 2014 |
| miR-16 | chr13: 50048973–50049061 (−) | Down | VEGFR2/p38/NF−κB | Human, in vitro | HP75 | Lu et al., 2018 |
| miR-93 | chr7: q22.1–q22.1 | Up | VEGF, IL-8 | Human, in vitro | U251, T98G | Fabbri et al., 2015 |
| miR-137 | chr1: p21.3–p21.3 | Down | VEGF | In vitro | U87MG, LN18 | Chakrabarti and Ray, 2015 |
| miR-21 | chr17: q23.1–q23.1 | Up | SNALP and RhoB | In vitro, in vivo | GL261 | Costa et al., 2015 |
| miR-21 | chr17: q23.1–q23.1 | Up | HIF-1α, VEGF | Human, in vitro | A172, U87, T98G | Hermansen et al., 2016 |
| miR−139−5p | chr11: q13.4–q13.4 | Down | Flt1 | Human, in vitro, in vivo | U87, SNB19, U251, LN308, LN229 | Wang Q. et al., 2018 |
| miR-494 | chr14: q32.31–q32.31 | Down | MMP-9, SDC1 | Human, in vitro, in vivo | D283 Med, D425, D341,D458, H2402,H2405, UW228 | Asuthkar et al., 2014 |
| miR-218 | chr4: p15.31–p15.31 | Down | RTK | Human, in vitro, in vivo | U87MG, U87-SCR, U87-218 | Mathew et al., 2014 |
| miR-29b | chr7: q32.3–q32.3 | Down | BCL2L2 | In vitro | U251, U87, U373 | Chung et al., 2015 |